Evaxion Biotech (EVAX) Tops Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Evaxion Biotech (EVAX) Tops Q1 EPS by 7c

Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update

May 13, 2021 7:30 AM EDT

Raised net proceeds of $27.9 million in U.S. initial public offering in February 2021Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2Product candidates EVX-03 and EVX-B1 progressing through pre-clinical developmentCash reserves of $27 million at March 31, 2021

COPENHAGEN, Denmark, May 13, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (Evaxion or the Company), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the first quarter 2021 financial results and... More